Table 2.

Measured blood variables stratified by WAT inflammation (n=154)

Variables Median (range)	CLS-P − (n=75)	CLS-P + (n=79)	P
Preoperative PSA*	5.79 (0.05,22.47)	5.90 (0.11,40.70)	0.14
Testosterone	5.81 (0.67,50.37)	5.98 (1.13,40.29)	0.81
Estradiol	30.15 (8.42,155.80)	30.58 (5.66,90.19)	0.46
SHBG	43.92 (9.09,96.51)	42.68 (16.90,127.05)	0.20
hsCRP (ng/mL)	1.09 (0.19,12.69)	2.06 (0.12,22.47)	0.06
Leptin (pg/mL)	5.04 (0.56,34.58)	7.54 (0.61,41.88)	0.11
Adiponectin (μg/mL)	7.58 (1.62,25.06)	5.64 (1.46,21.34)	0.01
Leptin/Adiponectin ratio	0.82 (0.02,19.01)	1.08 (0.04,11.91)	0.03
Glucose (mg/dL)	98.74 (73.22,165.94)	101.69 (40.21,282.30)	0.18
Insulin (mU/L)	6.01 (1.02,25.26)	6.86 (2.33,41.03)	0.02
HOMA2-IR	0.68 (0.11,3.17)	0.81 (0.26,4.60)	0.01
Total Cholesterol	178 (123,270)	187 (106,282)	0.83
LDL Cholesterol	110 (44,183)	110 (49,178)	0.99
HDL Cholesterol	50 (31,92)	46 (26,90)	0.03
Triglycerides	100 (48,363)	121 (44,457)	0.02

^*PSA was measured preoperatively and was available for 163 of the 169 men (CLS-P − n= 81, CLS-P + n=82)

Abbreviation: WAT, white adipose tissue; PSA, prostate-specific antigen; SHBG, sex hormone-binding globulin; hsCRP, high sensitivity C-reactive protein; HOMA2-IR, homeostasis model assessment 2 – insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein